Evaluation of the effect of fingolimod (FTY720) on macular perfusion by swept-source optical coherence tomography angiography in patients with multiple sclerosis

References

• Ochi H. Clinical features, diagnosis and therapeutic strategies in pediatric multiple sclerosis. Clin Exp Neuroimmunol 2017;8:33–39.
   Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–286.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Multiple  sclerosis review. P T 2012;37:175–184.
   PubMedGoogle Scholar
• Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013;73:625–650.
   PubMed Web of Science ®Google Scholar
• Mandal P, Gupta A, Fusi-Rubiano W, et al. Fingolimod: therapeutic mechanisms and ocular adverse effects. Eye 2017;31:232–240.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402–415.
   PubMed Web of Science ®Google Scholar
• Coppes OJM, Gutierrez I, Reder AT, et al. Severe early bilateral macular edema following fingolimod therapy. Mult Scler Relat Disord 2013;2:256–258.
   PubMed Web of Science ®Google Scholar
• Cugati S, Chen CS, Lake S, Lee AW. Fingolimod and macular edema: pathophysiology, diagnosis, and management. Neurol Clin Pract 2014;4:402–409.
   PubMedGoogle Scholar
• Zarbin MA, Jampol LM, Jager RD, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 2013;120:1432–1439.
   PubMed Web of Science ®Google Scholar
• Ueda N, Saida K. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. BMC Ophthalmol 2015;15:135.
   PubMed Web of Science ®Google Scholar
• Bhatti MT, Freedman SM, Mahmoud TH. Fingolimod therapy and macular hemorrhage. J Neuroophthalmol 2013;33:370–372.
   PubMed Web of Science ®Google Scholar
• Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology 2013;80:139–144.
   PubMed Web of Science ®Google Scholar
• Kal A, Ulusoy MO, Horasanli B, et al. Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis. Mult Scler Relat Disord 2017;14:4–7.
   PubMed Web of Science ®Google Scholar
• Turgut B. Optical coherence tomography angiography–a general view. Eur Ophthalmic Rev 2016;10:39–42.
   Google Scholar
• Wylęgała A, Teper S, Dobrowolski D, Wylęgała E. Optical coherence angiography: a review. Medicine 2016;95:e4907.
   PubMed Web of Science ®Google Scholar
• Kashani AH, Chen CL, Gahm JK, et al. Optical coherence tomography angiography: a comprehensive review of current methods and clinical applications. Prog Retin Eye Res 2017;60:66–100.
   PubMed Web of Science ®Google Scholar
• Al-Sheikh M, Falavarjani KG, Akil H, Sadda SR. Impact of image quality on OCT angiography based quantitative measurements. Int J Retina Vitreous 2017;3:13.
   PubMedGoogle Scholar
• Shin YU, Lee DE, Kang MH, et al. Optical coherence tomography angiography analysis of changes in the retina and the choroid after haemodialysis. Sci Rep 2018;8:1–10.
   PubMedGoogle Scholar
• Kuehlewein L, Tepelus TC, An L, et al. Noninvasive visualization and analysis of the human parafoveal capillary network using swept source OCT optical microangiography. Invest Ophthalmol Vis Sci 2015;56:3984–3988.
   PubMed Web of Science ®Google Scholar
• Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002;12:154–169.
   PubMed Web of Science ®Google Scholar
• Yilmaz H, Ersoy A, Icel E. Assessments of vessel density and foveal avascular zone metrics in multiple sclerosis: an optical coherence tomography angiography study. Eye 2020;34:771–778.
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Cennamo G, Criscuolo C, et al. Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. Mult Scler 2018;24:1706–1714.
   PubMed Web of Science ®Google Scholar
• Wang X, Jia Y, Spain R, et al. Optical coherence tomography angiography of optic nerve head and parafovea in multiple sclerosis. Br J Ophthalmol 2014;98:1368–1373.
   PubMed Web of Science ®Google Scholar
• Inglese M, Adhya S, Johnson G, et al. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab 2008;28:164–171.
   PubMed Web of Science ®Google Scholar
• Holland CM, Charil A, Csapo I, et al. The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1249 patients with multiple sclerosis. J Neuroimaging 2012;22:129–136.
   PubMed Web of Science ®Google Scholar
• Jasani KM, Sharaf N, Rog D, Aslam T. Fingolimod-associated macular oedema. 2017;2017:bcr2016218912.
   Google Scholar
• Turaka K, Bryan JS. Does fingolimod in multiple sclerosis patients cause macular edema? J Neurol 2012;259:386–388.
   PubMed Web of Science ®Google Scholar
• Feucht N, Maier M, Lepennetier G, et al. Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Mult Scler 2019;25:224–234.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041–1047.
   PubMed Web of Science ®Google Scholar
• Wang L, Murphy O, Caldito NG, et al. Emerging applications of Optical Coherence Tomography Angiography (OCTA) in neurological research. Eye Vis 2018;5:11.
   PubMedGoogle Scholar
• Ulusoy MO, Horasanli B, Isik-Ulusoy S. Optical coherence tomography angiography findings of multiple sclerosis with or without optic neuritis. Neurol Res 2020;42:319–326.
   PubMed Web of Science ®Google Scholar
• Campbell JP, Zhang M, Hwang TS, et al. Detailed vascular anatomy of the human retina by projection-resolved optical coherence tomography angiography. Sci Rep 2017;7:42201.
   PubMed Web of Science ®Google Scholar
• Afshar AR, Fernandes JK, Patel RD, et al. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol 2013;131:103–107.
   PubMed Web of Science ®Google Scholar
• Allen NB, Lichtman J, Cohen HW, et al. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 2008;30:234–238.
   PubMed Web of Science ®Google Scholar
• Nørgaard TL, Andersen CU, Hilt C, Andersen CU. Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod. Basic Clin Pharmacol Toxicol 2020;126:492–497.
   PubMed Web of Science ®Google Scholar
• Fruschelli M, Capozzoli M, Gelmi MC, Masi G, et al. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis. Int Ophthalmol 2019;39:777–781.
   PubMed Web of Science ®Google Scholar
• Winges KM, Werner JS, Harvey DJ, et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis. J Neuroophthalmol 2013;33:322–329.
   PubMed Web of Science ®Google Scholar
• Soliman MK, Sarwar S, Sadiq MA, et al. Acute onset of fingolimod-associated macular edema. Am J Ophthalmol Case Rep 2016;4:67–70.
   PubMedGoogle Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013;260:2023–2032.
   PubMed Web of Science ®Google Scholar